
The Urgent Need to Boost Cancer Patient Enrollment in Clinical Trials
In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer Network (NCCN), discusses the persistent challenges of low cancer patient enrollment in clinical trials and why broader participation is critical for advancing oncology research.
In a recent video interview with Applied Clinical Trials, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer Network (NCCN), discussed the current state and challenges of cancer patient participation in clinical trials. Barriers to participation can include lack of understanding, economic burdens, and implicit biases. Robinson highlighted solutions such as increased education, legislation like the Clinical Trials Modernization Act, and engaging patients early in trial design. He also touched on the use of technology, such as biomarker testing and wearable devices, which can also enhance recruitment and reduce burdens.
ACT: Could you elaborate on the current state of cancer patient participation in clinical trials and why it's a pressing issue for the clinical research industry?
Robinson: I just want to also start by saying thank you for the opportunity to discuss this really important topic. When you think about the current state of clinical trials, historically, if you go into the literature, it's been thought that participation has been very low, less than 5% of the patients actually participate in clinical trials, but a recent
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.